These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 2558600)

  • 21. Low-molecular-weight heparin for PE.
    Grimm KJ; French L
    J Fam Pract; 1997 Dec; 45(6):467-8. PubMed ID: 9420575
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of venous thrombosis with low molecular weight heparin. Progress and outlook].
    Fiessinger JN
    Bull Acad Natl Med; 1997 May; 181(5):875-83; discussion 883-5. PubMed ID: 9312362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary embolism in medical patients: improved diagnosis and the role of low-molecular-weight heparin in prevention and treatment.
    Merli GJ
    J Thromb Thrombolysis; 2004 Oct; 18(2):117-25. PubMed ID: 15789178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tinzaparin: new indication. Easier treatment of less severe pulmonary embolism.
    Prescrire Int; 2002 Feb; 11(57):13-5. PubMed ID: 11985368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of clinical trials of low molecular weight heparin fractions.
    Levine MN; Hirsh J
    Acta Chir Scand Suppl; 1988; 543():73-9. PubMed ID: 2847461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of venous thromboembolic disease using low molecular weight CY216 heparin in patients with high risk of hemorrhage].
    Prandoni P; Vigo M; Tropeano PF; Carletti E; Corbetti F; Antonello G; Cuppini S
    Ann Ital Med Int; 1988; 3(3):213-9. PubMed ID: 2856354
    [No Abstract]   [Full Text] [Related]  

  • 28. Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis?
    O'Connell MP; O'Leary M; MacKeogh L; Murphy K; Keane DP
    Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):12-4. PubMed ID: 15099863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of a very low molecular weight heparin fragment (CY 222) compared to standard heparin in patients with deep venous thrombosis. A randomized study].
    Faivre R; Neuhart E; Kieffer Y; Bassand JP; Maurat JP
    J Mal Vasc; 1987; 12 Suppl B():145-6. PubMed ID: 2834488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
    Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.
    Nguyen-Ho P; Levine GN
    Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biological monitoring of treatment with low molecular weight heparin].
    Aiach M; Sié P
    Ann Biol Clin (Paris); 1988; 46(9):715-8. PubMed ID: 2851948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [From prevention to therapy of thromboembolic processes: low-molecular heparin in body-weight adapted dosages].
    Internist (Berl); 1998 May; 39(5 Suppl Niedermole):1-16. PubMed ID: 9648001
    [No Abstract]   [Full Text] [Related]  

  • 34. Does low molecular weight heparin cause less bleeding?
    Thomas DP
    Thromb Haemost; 1997 Dec; 78(6):1422-5. PubMed ID: 9423787
    [No Abstract]   [Full Text] [Related]  

  • 35. [New heparins--does it change prevention and treatment of venous thrombosis?].
    Ikkala E; Myllylä G
    Duodecim; 1993; 109(20):1753-9. PubMed ID: 7736998
    [No Abstract]   [Full Text] [Related]  

  • 36. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
    Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-molecular-weight heparin for pulmonary embolism.
    Karne A; Shah NR
    Ann Intern Med; 2004 Sep; 141(5):407; author reply 407-8. PubMed ID: 15353437
    [No Abstract]   [Full Text] [Related]  

  • 38. [Apropos of the monitoring of treatment with low molecular weight heparins].
    Toulemonde F; Bayrou B
    Ann Biol Clin (Paris); 1989; 47(9):561-2. PubMed ID: 2558600
    [No Abstract]   [Full Text] [Related]  

  • 39. Low-molecular-weight heparin in the treatment of pulmonary embolism.
    Ageno W; Turpie AG
    Semin Vasc Surg; 2000 Sep; 13(3):189-93. PubMed ID: 11005462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.